SanDisk vs 22nd Century Group Inc — how do they compare? SanDisk trades at $1,581.91 (market cap $232.61B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: SanDisk is far larger — about 374169.6× 22nd Century Group Inc's market cap, and 22nd Century Group Inc is more actively traded (45,625 versus 9,218,054). Which is the better fit depends on your goals — on Pluang, investors hold SanDisk for 8 Days and 22nd Century Group Inc for 32 Days on average.
| SNDK | XXII | |
|---|---|---|
Market Cap | $232.61B | $621.67K |
Volume | 9,218,054 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $2.34K | $483.00 |
52-Week Low | $116.91 | $0.80 |
Typical Hold Time | 8 Days | 32 Days |
Enterprise Value | $228.03B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →